These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36870990)

  • 21. Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California.
    Ozga JE; Syvertsen JL; Pollini RA
    J Viral Hepat; 2022 Jul; 29(7):518-528. PubMed ID: 35357738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya.
    Akiyama MJ; Riback LR; Nyakowa M; Musyoki H; Lizcano JA; Muller A; Zhang C; Walker JG; Stone J; Vickerman P; Cherutich P; Kurth AE
    Int J Drug Policy; 2023 Mar; 113():103959. PubMed ID: 36758335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
    Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
    Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Barriers and facilitators of HIV and hepatitis C care among people who inject drugs in Nairobi, Kenya: a qualitative study with peer educators.
    Ludwig-Barron NT; Guthrie BL; Mbogo L; Bukusi D; Sinkele W; Gitau E; Farquhar C; Monroe-Wise A
    Harm Reduct J; 2021 Dec; 18(1):133. PubMed ID: 34922548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Service utilization and cost of implementing a comprehensive HIV prevention and care program among people who inject drugs in Delhi, India.
    Sebastian MP; Dasgupta A; Saraswati LR; Singh A; Sharma V; Madan I; Tun W; Pulerwitz J; Thior I; Sarna A
    Harm Reduct J; 2017 Jun; 14(1):38. PubMed ID: 28615077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decentralised same day test and treatment of hepatitis C levering existing peer support networks among men who inject drugs: feasibility and effectiveness.
    Rajkumar N; Khumukcham LS; Thangjam D; Singh S; Khwairakpam G; Shilton S; Goel A
    Harm Reduct J; 2024 May; 21(1):98. PubMed ID: 38769517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs.
    Tookes HE; Oxner A; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; McCollister K; Rodriguez A; Kolber MA; Chueng TA; Zayas S; McCoy B; Sutherland K; Archer C; Bartholomew TS
    Trials; 2023 Feb; 24(1):96. PubMed ID: 36750867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
    Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ;
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):153-161. PubMed ID: 29310928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study.
    Mirzazadeh A; Hosseini-Hooshyar S; Shahesmaeili A; Sharafi H; Shafiei M; Zarei J; Mousavian G; Tavakoli F; Ghalekhani N; Shokoohi M; Khezri M; Mehmandoost S; Shojaei MR; Karamouzian M; Briceno A; Morris MD; Alavian SM; Haghdoost AA; Sharifi H; Page KA
    Int J Drug Policy; 2022 Apr; 102():103580. PubMed ID: 35074607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integration of a geospatially targeted community-based testing approach with respondent-driven sampling to identify people who inject drugs living with HIV and HCV in Patti and Gorakhpur, India.
    Loeb TA; McFall AM; Srikrishnan AK; Anand S; Vasudevan CK; Mehta SH; Solomon SS
    Drug Alcohol Depend; 2023 Jun; 247():109874. PubMed ID: 37087926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis.
    Bao Y; Larney S; Peacock A; Colledge S; Grebely J; Hickman M; Degenhardt L; Leung J
    Int J Drug Policy; 2019 Aug; 70():87-93. PubMed ID: 31125802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infections among people who inject drugs in Kuwait: A cross-sectional study.
    Altawalah H; Essa S; Ezzikouri S; Al-Nakib W
    Sci Rep; 2019 Apr; 9(1):6292. PubMed ID: 31000775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs-Do Gender-Based Differences Vary by Country-Level Indicators?
    Leung J; Peacock A; Colledge S; Grebely J; Cunningham EB; Hickman M; Vickerman P; Stone J; Trickey A; Dumchev K; Lynskey M; Hines L; Griffiths P; Mattick RP; Degenhardt L; Larney S
    J Infect Dis; 2019 Jun; 220(1):78-90. PubMed ID: 30726973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study.
    Bouscaillou J; Kikvidze T; Butsashvili M; Labartkava K; Inaridze I; Etienne A; Le Pluart D; Kamkamidze G; Gamezardashvili A; Kharshiladze D; Avril E; Luhmann N
    Int J Drug Policy; 2018 Dec; 62():104-111. PubMed ID: 30384026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
    Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J;
    Int J Drug Policy; 2018 Nov; 61():23-30. PubMed ID: 30388566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations between the prevalence of chronic hepatitis B among people who inject drugs and country-level characteristics: An ecological analysis.
    Syangbo A; Hickman M; Colledge-Frisby S; Leung J; Grebely J; Larney S; Degenhardt L; Trickey A
    Drug Alcohol Rev; 2023 Mar; 42(3):569-581. PubMed ID: 36600489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates.
    Lens S; Miralpeix A; Gálvez M; Martró E; González N; Rodríguez-Tajes S; Mariño Z; Saludes V; Reyes-Urueña J; Majó X; Colom J; Forns X
    JHEP Rep; 2022 Dec; 4(12):100580. PubMed ID: 36316992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.